OLD National Bancorp IN Purchases 1,332 Shares of GSK plc (NYSE:GSK)

OLD National Bancorp IN lifted its position in shares of GSK plc (NYSE:GSK) by 13.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,106 shares of the pharmaceutical company’s stock after acquiring an additional 1,332 shares during the period. OLD National Bancorp IN’s holdings in GSK were worth $376,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Eastern Bank bought a new stake in shares of GSK in the 3rd quarter worth $26,000. ST Germain D J Co. Inc. boosted its position in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Concord Wealth Partners raised its position in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Finally, Fortitude Family Office LLC bought a new position in GSK during the 3rd quarter valued at about $42,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GSK shares. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

NYSE GSK opened at $35.20 on Friday. The business’s fifty day moving average is $34.07 and its 200 day moving average is $37.69. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a market capitalization of $72.96 billion, a PE ratio of 22.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.